Caplin Point Laboratories Share Price Target 2027: Base and Bull Targets Built on FY26 Earnings
- October 9, 2026
- Posted by: Lakshit Sharma
- Category: Market
Caplin Point Laboratories share price Rs 2,476.80 (9 October 2026). Base target Rs 3,022, bull Rs 3,651, downside risk Rs 2,040. PE 28.59. 52W range Rs 1,500.30 to Rs 2,990.00.
Quick Answer
The Caplin Point Laboratories share price target for 2027 is Rs 3,022, about 22.0% above the current price of Rs 2,476.80. The bull case is Rs 3,651, and the downside risk level, which is not a target, is Rs 2,040. The base case assumes earnings per share grow 18.5% a year, the pace seen from FY24 to FY26, with the stock holding its PE of 28.59. These are model-based estimates built from reported financials, not guaranteed outcomes.
Investors weighing a Caplin Point Laboratories target price for 2027 should start with where the stock sits today. At Rs 2,476.80 on 9 October 2026, it is 17.2% below its 52-week high of Rs 2,990.00 and 65.1% above its 52-week low of Rs 1,500.30. That range spans 99% from low to high, so the entry point matters as much as the Caplin Point Laboratories price forecast itself.
This article builds the Caplin Point Laboratories share price target from reported numbers only: five years of annual results, the last five quarters, the latest shareholding pattern and current valuation ratios from company filings and exchange data. Each scenario shows its assumptions, so you can see exactly how the Rs 3,022 base case and the Rs 3,651 bull case were reached, along with a downside risk level of Rs 2,040.
Click Here – Get Free Investment Predictions
Caplin Point Laboratories Stock Analysis: Company Overview and Key Stats
Caplin Point Laboratories (NSE: CAPLIPOINT) has a market capitalisation of Rs 19,388 crore. In FY26 it reported revenue of Rs 2,303 crore and net profit of Rs 649.73 crore. The table collects the figures the Caplin Point Laboratories share price target is built on.
| Metric | Value |
|---|---|
| Company | Caplin Point Laboratories |
| NSE Ticker | CAPLIPOINT |
| CMP (9 October 2026) | Rs 2,476.80 |
| 52-Week High | Rs 2,990.00 |
| 52-Week Low | Rs 1,500.30 |
| Market Cap | Rs 19,388 crore |
| PE Ratio (TTM) | 28.59 |
| Industry PE | 37.59 |
| Price to Book | 5.75 |
| Return on Equity | 17.88% |
| Debt to Equity | 0.00 |
| EPS (TTM) | Rs 89.20 |
| Dividend Yield | 0.31% |
| 12-Month Base Target | Rs 3,022 |
| Bull Case | Rs 3,651 |
| Downside Risk Level (not a target) | Rs 2,040 |
Why Is Caplin Point Laboratories Share Price Target Set at Rs 3,022 for 2027?
The base-case Caplin Point Laboratories stock target of Rs 3,022 applies a PE multiple of 28.59 to a forward EPS estimate of Rs 105.70. That EPS assumes 18.5% yearly growth, the pace from FY24 to FY26, and puts the target 22.0% above the current price. The bull case adds faster earnings growth and a higher multiple, while the downside risk level assumes flat earnings and a lower multiple.
Earnings Growth Behind the Caplin Point Laboratories Target Price: Five Years of Results
Caplin Point Laboratories grew revenue from Rs 1,308 crore in FY22 to Rs 2,303 crore in FY26, a compound annual growth rate of 15.2%. Net profit grew faster, from Rs 308.45 crore to Rs 649.73 crore (20.5% a year), which shows margin gains did part of the work and not just higher sales.
| Financial Year | Revenue (Rs Cr) | Net Profit (Rs Cr) | EPS (Rs) | Dividend per Share (Rs) |
|---|---|---|---|---|
| FY22 | 1,308.16 | 308.45 | 39.26 | 4.00 |
| FY23 | 1,522.71 | 376.99 | 49.18 | 4.50 |
| FY24 | 1,761.04 | 461.42 | 59.90 | 5.00 |
| FY25 | 2,033.90 | 541.09 | 70.25 | 6.00 |
| FY26 | 2,302.73 | 649.73 | 84.11 | 8.00 |
FY26 revenue growth was 13.2%, close to the four-year average of 15.2%, and net profit moved up 20.1%. EPS rose from Rs 59.90 in FY24 to Rs 84.11 in FY26. The FY27 outlook depends on whether that EPS estimate keeps compounding.
Margins and the Latest Quarter
Caplin Point Laboratories converted 28.2% of FY26 revenue into net profit, against 26.6% in FY25, within a five-year range of 23.6% to 28.2%. EBITDA margin was 38.1% in FY26 versus 36.5% in FY25.
In the June 2026 quarter, revenue was Rs 643.91 crore, up 20.7% from the same quarter a year earlier, while net profit of Rs 179.09 crore was up 18.8%. EBITDA came in at Rs 247.03 crore, up 23.0% year on year. The next quarterly result is the first test of whether the earnings assumption holds.
Balance Sheet and Cash Flow
Debt to equity stands at 0.00, and shareholders’ equity grew from Rs 1,510 crore in FY22 to Rs 3,631 crore in FY26. Operating cash flow in FY26 was Rs 523.24 crore against capital expenditure of Rs 248.13 crore, leaving free cash flow of Rs 275.11 crore, or 1.4% of the current market capitalisation. In FY25 free cash flow was Rs 240.85 crore.
Valuation Check for the Caplin Point Laboratories Stock Target: PE, Price to Book and ROE
At a PE of 28.59 against an industry PE of 37.59, Caplin Point Laboratories trades at a discount to its industry. Price to book is 5.75 on a book value of Rs 443.33 per share, and return on equity is 17.88%. A PE of 28.59 equals an earnings yield of 3.5%, and the FY26 dividend of Rs 8.00 per share gives a yield of 0.31%.
Shareholding Pattern and Institutional Holding
Promoters held 70.57% of Caplin Point Laboratories in June 2026, and promoter holding has stayed near 70.57% since June 2025. Foreign institutional investors (FII) held 5.75% and domestic institutions (DII) held 2.49%, which puts total institutional holding at 8.24%. FII holding fell from 6.17% in June 2025 to 5.75% in June 2026. Public shareholders own the remaining 21.18%.
Caplin Point Laboratories Share Price Targets for the Short Term and 12 Months
Short Term Caplin Point Laboratories Stock Target Levels: Technical Setup
At Rs 2,476.80 on 9 October 2026, Caplin Point Laboratories trades below its 50-day simple moving average of Rs 2,635.04 and above its 200-day exponential moving average of Rs 2,297.80. The 14-day RSI reads 30.6, which is neutral territory, and the MACD line sits below its signal line. The nearest resistance level is Rs 2,635.04 (50-day simple moving average) and the nearest support is Rs 2,297.80 (200-day exponential moving average). A sustained move above Rs 2,635.04 would improve the short-term setup, while a close below Rs 2,297.80 would shift attention to the next support.
12 Month Caplin Point Laboratories Target Price for 2027
The 12-month target for Caplin Point Laboratories is Rs 3,022: forward EPS of Rs 105.70 at a PE of 28.59. That is 22.0% above Rs 2,476.80. It would also push the stock above its 52-week high of Rs 2,990.00.
How EPS Growth and PE Multiple Change the Caplin Point Laboratories Target Price
| EPS Growth | PE 22.87 | PE 28.59 | PE 32.88 |
|---|---|---|---|
| 0.0% (EPS Rs 89.20) | Rs 2,040 | Rs 2,550 | Rs 2,933 |
| 18.5% (EPS Rs 105.70) | Rs 2,417 | Rs 3,022 | Rs 3,475 |
| 24.5% (EPS Rs 111.05) | Rs 2,540 | Rs 3,175 | Rs 3,651 |
Each cell multiplies the forward EPS estimate by the PE shown. Reading across a row shows what a de-rating or re-rating does to the Caplin Point Laboratories price forecast, and reading down a column shows what earnings growth is worth at a fixed multiple.
Bull Case and Downside Risk for Caplin Point Laboratories Stock Target in 2027
Bull Case Rs 3,651
The bull case Caplin Point Laboratories price target needs EPS growth of 24.5%, which lifts forward EPS to Rs 111.05, and a PE multiple that rises 15% to 32.88. That gives Rs 3,651, 47.4% above the current price and above the 52-week high of Rs 2,990.00, so the stock would have to set a fresh 52-week high.
Downside Risk Level Rs 2,040
The downside risk level is not a target. It assumes EPS stays flat at Rs 89.20 and the PE falls 20% to 22.87. That gives Rs 2,040, 17.6% below the current price and above the 52-week low of Rs 1,500.30.
| Scenario | EPS Growth | PE Multiple | Price (Rs) | Change vs CMP |
|---|---|---|---|---|
| Bull Case | 24.5% | 32.88 | Rs 3,651 | +47.4% |
| Base Case | 18.5% | 28.59 | Rs 3,022 | +22.0% |
| Downside Risk | 0.0% | 22.87 | Rs 2,040 | -17.6% |
Key Risks to the Caplin Point Laboratories Target Price for 2027
Growth Slowdown Risk for the Caplin Point Laboratories Price Target
Revenue in the June 2026 quarter was up 20.7% year on year, and FY26 revenue growth was 13.2%. If growth slows from here, the EPS estimate behind the Caplin Point Laboratories stock target will need revising.
Liquidity and Size Risk
Caplin Point Laboratories has a market capitalisation of Rs 19,388 crore. Institutional holding is 8.24%, and promoters hold 70.57%. Stocks of this size are usually liquid, though exits can take longer than entries when the market is falling.
Valuation and Margin Risk
Net margin was 28.2% in FY26, and a squeeze from higher costs or weaker pricing would hit earnings first. At a PE of 28.59 versus an industry PE of 37.59, a de-rating toward the downside-risk PE of 22.87 would cut the price even if earnings hold.
Market and Technical Risk
The stock trades 17.2% below its 52-week high, with an RSI of 30.6 and a MACD reading below its signal line. Broader market weakness can override company fundamentals in the short term.
How to Invest in Caplin Point Laboratories
Start with the live price and volume. Any Caplin Point Laboratories share price target is only as current as the data behind it, and the data here is as of 9 October 2026, so refresh the Rs 2,476.80 price before acting on any level.
Next, review the fundamentals yourself. The Univest Screener lets you check Caplin Point Laboratories’ PE, ROE, debt and shareholding in one place.
Check Caplin Point Laboratories fundamentals on the Univest Screener
Then compare the three Caplin Point Laboratories target price scenarios with your own view. If you expect EPS growth below 18.5%, the base case is too optimistic for you; if you expect more, the bull case deserves weight.
Decide your position size and exit levels before you buy. The support and resistance levels above can serve as reference points, but they are not recommendations.
Finally, place the order through a SEBI-registered broker or the Univest app, and review the position after each quarterly result. Consult a SEBI-registered advisor if you are unsure.
Download the Univest iOS App or Univest Android App to track Caplin Point Laboratories live price and get daily stock recommendations.
Conclusion
The Caplin Point Laboratories share price target for 2027 is Rs 3,022 in the base case, with Rs 3,651 as the bull case. The support for that view is arithmetic you can check: EPS grew 18.5% a year over FY24 to FY26, and the stock trades at a PE of 28.59. The risks are equally concrete, including a stock that sits 17.2% below its 52-week high and a downside scenario that cuts the price 18% if earnings stall. Use these numbers as a framework, check them against the latest filings, and size any position to your own risk appetite.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Caplin Point Laboratories Share Price Target 2027
What is the Caplin Point Laboratories share price target for 2027?
Ans. The base-case Caplin Point Laboratories share price target for 2027 is Rs 3,022, with Rs 3,651 as the bull case. The downside risk level, which is not a target, is Rs 2,040. These are model estimates from reported earnings and the current PE, not guaranteed outcomes.
What is the Caplin Point Laboratories share price today?
Ans. As of 9 October 2026, 12:52 PM IST, Caplin Point Laboratories trades at Rs 2,476.80, down 2.82% on the day. The 52-week range is Rs 1,500.30 to Rs 2,990.00.
Is Caplin Point Laboratories a buy or sell at the current price?
Ans. The data is mixed rather than one-sided: EPS has grown 18.5% a year over FY24 to FY26, but the stock is 17.2% below its 52-week high. Whether Caplin Point Laboratories fits your portfolio depends on your time horizon and risk appetite, so consult a SEBI-registered advisor before investing. This article is not investment advice.
What are the bull case target and downside risk level for Caplin Point Laboratories shares?
Ans. The bull case target is Rs 3,651, which assumes 24.5% EPS growth and a PE of 32.88. The downside risk level is Rs 2,040, which assumes flat EPS and a PE of 22.87. It marks a risk, not a target.
What are the main risks to the Caplin Point Laboratories price target?
Ans. The main risks are slower revenue growth, a small market capitalisation of Rs 19,388 crore, a PE de-rating and short-term weakness in the broader market. Each is covered in the risk section above.
What is the PE ratio of Caplin Point Laboratories and how does it compare with the industry?
Ans. The PE ratio of Caplin Point Laboratories is 28.59 against an industry PE of 37.59. Price to book is 5.75 and return on equity is 17.88%. The base case in the Caplin Point Laboratories price target holds this PE constant.
Who owns Caplin Point Laboratories, and what is the promoter holding?
Ans. Promoters held 70.57% of Caplin Point Laboratories in June 2026. FII held 5.75%, DII held 2.49% and the public held 21.18%.
What were Caplin Point Laboratories’ latest quarterly results?
Ans. In the June 2026 quarter, Caplin Point Laboratories reported revenue of Rs 643.91 crore (up 20.7% year on year) and net profit of Rs 179.09 crore (up 18.8%).